Therapeutic monitoring of von Willebrand disease: Interest and limits of a platelet function analyser at high shear rates

British Journal of Haematology

Volumn 106, Issue 3, 1999, Pages 777-783

  Fressinaud, Edith ^a   Veyradier, Agnès ^b   Sigaud, Marianne ^a   Boyer Neumann, Catherine ^b   Le Boterff, Cécile ^a   Meyer, Dominique ^b,c  

^a HÔTEL DIEU   (France)

^b HÔPITAL ANTOINE BÉCLÈRE   (France)

^c Dept Environ Med Natl Inst Publ HIth   (Norway)

Author keywords

Closure time (PFA 100(TM)); Desmopressin; Von Willebrand disease; Von Willebrand factor; VWP concentrates

Indexed keywords

ADULT; ARTICLE; BLEEDING TIME; CLINICAL ARTICLE; DIAGNOSTIC VALUE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SHEAR STRESS; THROMBOCYTE ADHESION; THROMBOCYTE FUNCTION; VON WILLEBRAND DISEASE;

ADOLESCENT; ADULT; BLEEDING TIME; CHILD; CHILD, PRESCHOOL; DEAMINO ARGININE VASOPRESSIN; FEMALE; HEMOSTATICS; HUMANS; MALE; MIDDLE AGED; PLATELET FUNCTION TESTS; SENSITIVITY AND SPECIFICITY; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 0032878391     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1999.01604.x     Document Type: Article

References (22)

1. Castaman, G. & Rodeghiero, F. (1996) Desmopressin and type HB von Willebrand disease. Haemophilia, 2, 73-75.
2. Castillo, R., Escolar, G., Monteagudo, J., Aznar-Salatti, J., Reverter, J.C. & Ordinas, A. (1997) Hemostasis in patients with severe von Willebrand disease improves after normal platelet transfusion and normalizes with further correction of the plasma defect. Transfusion, 37, 785-790.
3. Castillo, R., Monteagudo, J., Escolar, G., Ordinas, A., Magallon, M. & Martin Villar, J. (1991) Hemostatic effect of normal platelet transfusion in severe von Willebrand disease. Blood, 77, 1901-1905.
4. Chang, A.C., Jacobs, H., Weinstein, M.J. & Kessler, C.M. (1998) The correlation of closure time and von Willebrand factor activity of factor VIII concentrates. Blood, 92, (Suppl. 1), 184a.
5. Fressinaud, E., Federici, A.B., Castaman, G., Rothschild, C., Rodeghiero, F., Baumgartner, H.R., Mannucci, P.M. & Meyer, D. (1994) The role of platelet von Willebrand factor in platelet adhesion and thrombus formation: a study of 34 patients with various subtypes of type I von Willebrand disease. British Journal of Haematology, 86, 327-332.
6. Fressinaud, E., Veyradier, A., Truchaud, F., Martin, I., Boyer-Neumann, C., Trossaert, M. & Meyer, D. (1998) Screening for von Willebrand disease with a new analyzer utilizing high shear stress: a study of 60 cases. Blood, 91, 1325-1331.
7. Gralnick, H.R., Rick, M.E., McKeown, L.P., Williams, S.B., Parker, R.I., Maisonneuve, P., Jeanneau, C. & Sultan, Y. (1986) Platelet von Willebrand factor: an important determinant of the bleeding time in type I von Willebrand's disease. Blood, 68, 58-61.
8. Kundu, S.K., Heilmann, E., Sio, R., Garcia, C. & Ostgaart, R. (1996) Characterization of an in vitro platelet function analyzer, PFA-100™. Clinical and Applied Thrombosis/Hemostasis, 2, 241-249.
9. Lyons, S.E., Bruck, M.E., Bowie, E.J.W. & Ginsburg, D. (1992) Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations. Journal of Biological Chemistry, 267, 4424-4430.
10. Mannucci, P.M. (1995) Platelet von Willebrand factor in inherited and acquired bleeding disorders. Proceedings of the National Academy of Sciences of the United States of America, 92, 2428-2432.
11. Mannucci, P.M. (1997) Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood, 90, 2515-2521.
12. Mannucci, P.M., Lattuada, A. & Ruggeri, Z.M. (1994) Proteolysis of von Willebrand factor in therapeutic plasma concentrates. Blood, 83, 3018-3027.
13. Mannucci, P.M., Lombardi, R., Bader, R., Vianello, L., Federici, A.S., Solinas, S., Mazzucconi, M.G. & Mariani, G. (1985) Heterogeneity of type I von Willebrand disease: evidence for a subgroup with an abnormal von Willebrand factor. Blood, 66, 796-802.
14. Mannucci, P.M., Ruggeri, Z.M., Pareti, F.I. & Capitanio, A. (1977) 1-Deamino-8-d arginine vasopressine: a new pharmacological approach to the management of haemophilia and von Willebrand's diseases. Lancet, i, 869-872.
15. Mannucci, P.M., Tenconi, P.M., Castaman, G. & Rodeghiero, F. (1992) Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial. Blood, 79, 3130-3137.
16. Meyer, D., Fressinaud, E., Gaucher, C., Lavergne, J.M., Hilbert, L., Ribba, A.S., Jorieux, S., Mazurier, C., and the INSERM Network on molecular abnormalities in von Willebrand disease (1997) Gene defects in 150 unrelated French cases with type 2 von Willebrand disease: from the patient to the gene. Thrombosis and Haemostasis, 78, 451-456.
17. Meyer, D., Obert, B., Piétu, G., Lavergne, J.M. & Zimmerman, T.S. (1980) Multimeric structure of factor VIII/von Willebrand factor in von Willebrand's disease. Journal of Laboratory and Clinical Medicine, 95, 590-602.
18. Nichols, W.C. & Ginsburg, D. (1997) von Willebrand disease. Reviews in Molecular Medicine, 76, 1-20.
19. Rabinowitz, I., Tuley, E.A., Mancuso, D.J., Randi, A.M., Firkin, B.G., Howard, M.A. & Sadler, J.E. (1992) von Willebrand disease type B: a missense mutation selectively abolishes ristocetin-induced von Willebrand factor binding to platelet glycoprotein Ib. Proceedings of the National Academy of Sciences of the United States of America, 89, 9846-9849.
20. Rodeghiero, F., Castaman, G. & Dini, E. (1987) Epidemiological investigation of the prevalence of von Willebrand's disease. Blood, 69, 454-459.
21. Rodeghiero, F., Castaman, G., Meyer, D. & Mannucci, P.M. (1992) Replacement therapy with virus-inactivated plasma concentrates in von Willebrand disease. Vox Sanguinis, 62, 193-199.
22. Sadler, J.E. (1994) A revised classification of von Willebrand disease. Thrombosis and Haemostasis, 71, 520-525.